Advocacy intelligence hub — real-time data for patient organizations
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs1
Repatha
Amgen Inc.
Praluent
(alirocumab)Orphan drugstandardRegeneron Pharmaceuticals, Inc.
PCSK9 Inhibitor [EPC]
12.1 Mechanism of Action Alirocumab is a human monoclonal antibody that binds to proprotein convertase subtilisin kexin type 9 (PCSK9). PCSK9 binds to...
Repatha
(evolocumab)Orphan drugstandardAmgen Inc.
PCSK9 Inhibitor [EPC]
12.1 Mechanism of Action Evolocumab is a human monoclonal IgG2 directed against human proprotein convertase subtilisin kexin type 9 (PCSK9). PCSK9 bin...
Browse all Triglyceride deposit cardiomyovasculopathy news →
Kenichi Hirano, MD, Ph.D
Department of Cardiovascular Medicine, Faculty of Internal Medicine, Graduate School of Osaka University
Ken-ichi Hirano, MD, PhD
Department of Triglyceride Science, Graduate School of Medicine, Osaka University
View all Triglyceride deposit cardiomyovasculopathy specialists →